Video Journal of Hematology & Hematological Oncology (VJHemOnc)’s Post

We are thrilled to bring you a NEW CME accredited feature on 'Practical Considerations for CAR-T Therapy in #Hematological Malignancies' 🗞️ 🔦 Hear from leaders in the field on how to identify, refer, and monitor patients with #multiplemyeloma, #lymphoma, or #acutelymphoblasticleukemia (#ALL) who receive #CARTtherapy 🩺🩸🔦 We cover: 💡 Practicalities Of CAR-T Therapy For Patients With Multiple #Myeloma 💡 Practicalities Of CAR-T Therapy For Patients With #Lymphoma 💡 Practicalities Of CAR-T Therapy For Patients With #ALL 💡 Understanding The CAR-T Therapy Process 💡 Current Status Of CAR-T Therapy For #Pediatric And AYA Patients 💡 Measuring And Managing #Toxicities Following CAR-T Therapy Explore the feature 👉 https://lnkd.in/eBX9gZHb Earn 1.5 CME credits ✅ Partners for Advancing Clinical Education (PACE) accreditation information can be found on this linked page 👉 https://lnkd.in/eBX9gZHb #HemOnc #Hematologynews #CMEaccredited #Leusm #Lymsm #MMsm

We are thrilled to bring you a NEW CME accredited feature on 'Practical Considerations for CAR-T Therapy in #Hematological Malignancies' 🗞️ 🔦 Hear from leaders in the field on how to identify, refer, and monitor patients with #multiplemyeloma, #lymphoma, or #acutelymphoblasticleukemia (#ALL) who receive #CARTtherapy 🩺🩸🔦 We cover: 💡 Practicalities Of CAR-T Therapy For Patients With Multiple #Myeloma 💡 Practicalities Of CAR-T Therapy For Patients With #Lymphoma 💡 Practicalities Of CAR-T Therapy For Patients With #ALL 💡 Understanding The CAR-T Therapy Process 💡 Current Status Of CAR-T Therapy For #Pediatric And AYA Patients 💡 Measuring And Managing #Toxicities Following CAR-T Therapy Explore the feature 👉 https://lnkd.in/eBX9gZHb Earn 1.5 CME credits ✅ Partners for Advancing Clinical Education (PACE) accreditation information can be found on this linked page 👉 https://lnkd.in/eBX9gZHb #HemOnc #Hematologynews #CMEaccredited #Leusm #Lymsm #MMsm

We are thrilled to bring you a NEW CME accredited feature on 'Practical Considerations for CAR-T Therapy in #Hematological Malignancies' 🗞️ 🔦 Hear from leaders in the field on how to identify, refer, and monitor patients with #multiplemyeloma, #lymphoma, or #acutelymphoblasticleukemia (#ALL) who receive #CARTtherapy 🩺🩸🔦 We cover: 💡 Practicalities Of CAR-T Therapy For Patients With Multiple #Myeloma 💡 Practicalities Of CAR-T Therapy For Patients With #Lymphoma 💡 Practicalities Of CAR-T Therapy For Patients With #ALL 💡 Understanding The CAR-T Therapy Process 💡 Current Status Of CAR-T Therapy For #Pediatric And AYA Patients 💡 Measuring And Managing #Toxicities Following CAR-T Therapy Explore the feature 👉 https://lnkd.in/eBX9gZHb Earn 1.5 CME credits ✅ Partners for Advancing Clinical Education (PACE) accreditation information can be found on this linked page 👉 https://lnkd.in/eBX9gZHb #HemOnc #Hematologynews #CMEaccredited #Leusm #Lymsm #MMsm

We are thrilled to bring you a NEW CME accredited feature on 'Practical Considerations for CAR-T Therapy in #Hematological Malignancies' 🗞️ 🔦 Hear from leaders in the field on how to identify, refer, and monitor patients with #multiplemyeloma, #lymphoma, or #acutelymphoblasticleukemia (#ALL) who receive #CARTtherapy 🩺🩸🔦 We cover: 💡 Practicalities Of CAR-T Therapy For Patients With Multiple #Myeloma 💡 Practicalities Of CAR-T Therapy For Patients With #Lymphoma 💡 Practicalities Of CAR-T Therapy For Patients With #ALL 💡 Understanding The CAR-T Therapy Process 💡 Current Status Of CAR-T Therapy For #Pediatric And AYA Patients 💡 Measuring And Managing #Toxicities Following CAR-T Therapy Explore the feature 👉 https://lnkd.in/eBX9gZHb Earn 1.5 CME credits ✅ Partners for Advancing Clinical Education (PACE) accreditation information can be found on this linked page 👉 https://lnkd.in/eBX9gZHb #HemOnc #Hematologynews #CMEaccredited #Leusm #Lymsm #MMsm

Patients with DRE need a progressive intervention beyond medication. • 20% of ASMs are discontinued within 6 months due to adverse effects, even at low doses1 • Without a way to control their seizures, patients and caregivers suffer consequences in their daily life2,3 • Polypharmacy (>3 ASMs) is associated with poor cognitive and psychosocial outcomes, with significant risk for special education placement and impaired social contact3 VNS Therapy™ is a non-drug option that can break the cycle of multiple anti-seizure medication failures. The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications. To learn more about VNS Therapy visit: https://bit.ly/3YCyn2q Important safety information: https://lnkd.in/dSQ3BYgK References: 1. Alsfouk BAA, Brodie MJ, Walters M, Kwan P, Chen Z. JAMA neurol. 2020;77(5):574-581. 2. Berg AT, Zelko FA, Levy SR, Testa FM. Neurology. 2012;79(13):1384-1391. 3. Valova V, Kochan A, Werry B, et al. Neuropediatrics. 2020;51(2):164-169.

Patients with DRE need a progressive intervention beyond medication. • 20% of ASMs are discontinued within 6 months due to adverse effects, even at low doses1 • Without a way to control their seizures, patients and caregivers suffer consequences in their daily life2,3 • Polypharmacy (>3 ASMs) is associated with poor cognitive and psychosocial outcomes, with significant risk for special education placement and impaired social contact3 VNS Therapy™ is a non-drug option that can break the cycle of multiple anti-seizure medication failures. The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications. To learn more about VNS Therapy visit: https://bit.ly/3YCyn2q Important safety information: https://lnkd.in/dSQ3BYgK References: 1. Alsfouk BAA, Brodie MJ, Walters M, Kwan P, Chen Z. JAMA neurol. 2020;77(5):574-581. 2. Berg AT, Zelko FA, Levy SR, Testa FM. Neurology. 2012;79(13):1384-1391. 3. Valova V, Kochan A, Werry B, et al. Neuropediatrics. 2020;51(2):164-169.

Patients with DRE need a progressive intervention beyond medication. • 20% of ASMs are discontinued within 6 months due to adverse effects, even at low doses1 • Without a way to control their seizures, patients and caregivers suffer consequences in their daily life2,3 • Polypharmacy (>3 ASMs) is associated with poor cognitive and psychosocial outcomes, with significant risk for special education placement and impaired social contact3 VNS Therapy™ is a non-drug option that can break the cycle of multiple anti-seizure medication failures. The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications. To learn more about VNS Therapy visit: https://bit.ly/3YCyn2q Important safety information: https://lnkd.in/dSQ3BYgK References: 1. Alsfouk BAA, Brodie MJ, Walters M, Kwan P, Chen Z. JAMA neurol. 2020;77(5):574-581. 2. Berg AT, Zelko FA, Levy SR, Testa FM. Neurology. 2012;79(13):1384-1391. 3. Valova V, Kochan A, Werry B, et al. Neuropediatrics. 2020;51(2):164-169.

Patients with DRE need a progressive intervention beyond medication. • 20% of ASMs are discontinued within 6 months due to adverse effects, even at low doses1 • Without a way to control their seizures, patients and caregivers suffer consequences in their daily life2,3 • Polypharmacy (>3 ASMs) is associated with poor cognitive and psychosocial outcomes, with significant risk for special education placement and impaired social contact3 VNS Therapy™ is a non-drug option that can break the cycle of multiple anti-seizure medication failures. The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications. To learn more about VNS Therapy visit: https://bit.ly/3YCyn2q Important safety information: https://lnkd.in/dSQ3BYgK References: 1. Alsfouk BAA, Brodie MJ, Walters M, Kwan P, Chen Z. JAMA neurol. 2020;77(5):574-581. 2. Berg AT, Zelko FA, Levy SR, Testa FM. Neurology. 2012;79(13):1384-1391. 3. Valova V, Kochan A, Werry B, et al. Neuropediatrics. 2020;51(2):164-169.

Patients with DRE need a progressive intervention beyond medication. • 20% of ASMs are discontinued within 6 months due to adverse effects, even at low doses1 • Without a way to control their seizures, patients and caregivers suffer consequences in their daily life2,3 • Polypharmacy (>3 ASMs) is associated with poor cognitive and psychosocial outcomes, with significant risk for special education placement and impaired social contact3 VNS Therapy™ is a non-drug option that can break the cycle of multiple anti-seizure medication failures. The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications. To learn more about VNS Therapy visit: https://bit.ly/3YCyn2q Important safety information: https://lnkd.in/dSQ3BYgK References: 1. Alsfouk BAA, Brodie MJ, Walters M, Kwan P, Chen Z. JAMA neurol. 2020;77(5):574-581. 2. Berg AT, Zelko FA, Levy SR, Testa FM. Neurology. 2012;79(13):1384-1391. 3. Valova V, Kochan A, Werry B, et al. Neuropediatrics. 2020;51(2):164-169.

Patients with DRE need a progressive intervention beyond medication. • 20% of ASMs are discontinued within 6 months due to adverse effects, even at low doses1 • Without a way to control their seizures, patients and caregivers suffer consequences in their daily life2,3 • Polypharmacy (>3 ASMs) is associated with poor cognitive and psychosocial outcomes, with significant risk for special education placement and impaired social contact3 VNS Therapy™ is a non-drug option that can break the cycle of multiple anti-seizure medication failures. The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications. To learn more about VNS Therapy visit: https://bit.ly/3YCyn2q Important safety information: https://lnkd.in/dSQ3BYgK References: 1. Alsfouk BAA, Brodie MJ, Walters M, Kwan P, Chen Z. JAMA neurol. 2020;77(5):574-581. 2. Berg AT, Zelko FA, Levy SR, Testa FM. Neurology. 2012;79(13):1384-1391. 3. Valova V, Kochan A, Werry B, et al. Neuropediatrics. 2020;51(2):164-169.